Floatz logo

Bemotuzumab

Chemotherapy Effects

Zhejiang Provincial People's HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Chemotherapy Effects cohort.

Asset / SponsorPhaseRating
Carboplatin
Zhejiang Provincial People's Hospital
N/AD
Epirubicin
Zhejiang Provincial People's Hospital
N/AD
Cyclophosphamide
Zhejiang Provincial People's Hospital
N/AD

Same molecule, other indications

Bemotuzumab is also rated in:

SCLC, Extensive StageDormant
CCC
Indicative ·
53 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
cancerDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →